Back to GetFilings.com





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 2, 2005

 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition period from             to

Commission File Number: 0-27598

IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
 
77-0210467
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. employer
identification No.)

1212 Terra Bella Avenue
Mountain View, California 94043-1824
(Address of principal executive offices, including zip code)

(650) 940-4700
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No o
 
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o Nox
 
 
APPLICABLE TO CORPORATE ISSUERS:

The number of shares of common stock, $.01 par value, issued and outstanding as of May 10, 2005 was 7,433,298.



IRIDEX Corporation
 
Table of Contents

     
Page
PART I.
   
       
Item 1.
   
       
   
   3
       
    4
       
    5
   
 
 
   
6
       
   
7
       
Item 2.
  12
       
Item 3.
 
27
       
Item 4.
 
27
       
PART II.
   
       
Item 1.
 
28
       
Item 2.
 
28
       
Item 3.
 
28
       
Item 4.
 
28
       
Item 5.
 
28
       
Item 6.
 
28
       
   
29
       
30
       
Exhibit 31.1
 
Certification of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
 
       
Exhibit 31.2
 
Certification of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
 
       
Exhibit 32.1
 
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
2

 
Part I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements


IRIDEX Corporation
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
 
   
April 2,
2005
 
January 1,
2005
 
Assets
         
Current assets:
         
Cash and cash equivalents
 
$
6,202
 
$
10,381
 
Available-for-sale securities
   
8,907
   
3,323
 
Accounts receivable, net
   
6,848
   
7,404
 
Inventories
   
9,511
   
8,922
 
Prepaids and other current assets
   
1,078
   
814
 
Current deferred income taxes
   
1,808
   
1,808
 
Total current assets
   
34,354
   
32,652
 
Long term portion of available-for-sale securities
   
1,535
   
4,324
 
Property and equipment, net
   
854
   
852
 
Deferred income taxes
   
1,265
   
1,265
 
Total assets
 
$
38,008
 
$
39,093
 
               
Liabilities and Stockholders’ Equity
             
Current liabilities:
             
Accounts payable
 
$
1,179
 
$
1,233
 
Accrued expenses
   
4,058
   
5,167
 
Deferred revenue
   
962
   
910
 
Total liabilities
   
6,199
   
7,310
 
               
Stockholders’ equity:
             
Common stock
   
74
   
74
 
Additional paid-in capital
   
25,352
   
25,281
 
Accumulated other comprehensive loss
   
(60
)
 
(35
)
Treasury stock
   
(430
)
 
(430
)
Retained earnings
   
6,873
   
6,893
 
Total stockholders’ equity
   
31,809
   
31,783
 
Total liabilities and stockholders’ equity
 
$
38,008
 
$
39,093
 

 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
3


IRIDEX Corporation
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
 
   
Three Months Ended
 
   
April 2,
2005
 
April 3,
2004
 
           
Sales
 
$
8,145
 
$
7,392
 
Cost of sales
   
4,467
   
4,177
 
Gross profit
   
3,678
   
3,215
 
               
Operating expenses:
             
Research and development
   
1,039
   
1,107
 
Sales, general and administrative
   
2,797
   
2,193
 
Total operating expenses
   
3,836
   
3,300
 
               
Loss from operations
   
(158
)
 
(85
)
Interest and other income, net
   
126
   
60
 
Loss before income taxes
   
(32
)
 
(25
)
Benefit from income taxes
   
12
   
8
 
Net loss
 
$
(20
)
$
(17
)
               
Net loss per share - basic and diluted
 
$
( 0.00
)
$
( 0.00
)
               
Shares used in computing net loss per share - basic and diluted
   
7,317
   
7,076
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4

 
IRIDEX Corporation
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

   
Three Months Ended
 
   
April 2,
 
April 3,
 
   
2005
 
2004
 
Cash flows from operating activities:
         
Net loss
 
$
(20
)
$
(17
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
             
Depreciation and amortization
   
113